MariMed - MRMD Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRMD shares.
View MRMD analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1-year price targets for MariMed's stock. Their MRMD share price forecasts range from $0.85 to $0.85. On average, they anticipate the company's share price to reach $0.85 in the next twelve months. This suggests a possible upside of 106.3% from the stock's current price.
View analysts price targets for MRMD or view top-rated stocks among Wall Street analysts.

MariMed's stock was trading at $0.3562 at the beginning of 2023. Since then, MRMD stock has increased by 15.7% and is now trading at $0.4120.
View the best growth stocks for 2023 here.

MariMed saw a decline in short interest in December. As of December 15th, there was short interest totaling 9,900 shares, a decline of 23.3% from the November 30th total of 12,900 shares. Based on an average daily volume of 1,117,200 shares, the short-interest ratio is currently 0.0 days.
View MariMed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our MRMD earnings forecast.

MariMed Inc. (OTCMKTS:MRMD) posted its quarterly earnings data on Monday, November, 7th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The business earned $33.91 million during the quarter, compared to the consensus estimate of $34.20 million. MariMed had a net margin of 1.79% and a trailing twelve-month return on equity of 5.18%.

MariMed updated its FY 2022 earnings guidance on Monday, November, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $132.00 million-$135.00 million, compared to the consensus revenue estimate of $135.80 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other MariMed investors own include KushCo (KSHB), Organigram (OGI), Auxly Cannabis Group (CBWTF), CNBX Pharmaceuticals (CNBX), Supreme Cannabis (SPRWF), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), GB Sciences (GBLX), Medical Marijuana (MJNA) and Smart Cannabis (SCNA).

MariMed trades on the OTCMKTS under the ticker symbol "MRMD."

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRMD stock can currently be purchased for approximately $0.41.

MariMed (OTCMKTS:MRMD) has a market capitalization of $139.86 million and generates $121.46 million in revenue each year.

The company employs 260 workers across the globe.

MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The official website for the company is marimedadvisors.com. The company can be reached via phone at (617) 795-5140 or via email at ir@mattio.com.